Chronic wounds remain a pressing global health challenge, exacerbated by comorbid conditions such as diabetes and vascular disorders. Traditional wound care methods often fall short in managing non-healing wounds, leading to increased morbidity and healthcare costs. Recent advancements in biomedical research have paved the way for novel strategies to enhance and accelerate the wound healing process. Bioengineered dressings, such as hydrocolloids and scaffolds like Integra®, offer enhanced moisture retention and support tissue regeneration. Nanotechnology introduces antimicrobial nanoparticles and smart drug delivery systems that directly target the wound environment, reducing infection and promoting cell proliferation. Mesenchymal stem cells (MSCs) and extracellular vesicles (EVs) offer regenerative and immunomodulatory capabilities, enhancing angiogenesis and re-epithelialization while minimizing inflammation. Advanced materials like hydrogels and microneedle patches allow for sustained and localized release of bioactive agents, improving therapeutic outcomes. Moreover, 3D-printed scaffolds, designed to mimic the extracellular matrix, support cellular migration and tissue integration, while innovations in biomaterial biocompatibility reduce immune rejection. Artificial Intelligence (AI) further augments wound monitoring through predictive analytics and remote diagnostics, offering scalable solutions in resource-limited settings like rural India. Despite the promise of these technologies, challenges such as high production costs, regulatory bottlenecks, and infrastructure disparities limit widespread clinical adoption. Addressing these barriers through collaborative efforts, policy reform, and equitable healthcare strategies is essential. The integration of emerging biotechnologies with personalized medicine holds transformative potential for revolutionizing wound care and achieving scar-free, regenerative healing.